Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients' own inflammatory cells, platelets and growth factors: the first introduction to the low speed centrifugation concept

J Choukroun, S Ghanaati, J Choukroun, S Ghanaati

Abstract

Purpose: The aim of this study was to analyze systematically the influence of the relative centrifugation force (RCF) on leukocytes, platelets and growth factor release within fluid platelet-rich fibrin matrices (PRF).

Materials and methods: Systematically using peripheral blood from six healthy volunteers, the RCF was reduced four times for each of the three experimental protocols (I-III) within the spectrum (710-44 g), while maintaining a constant centrifugation time. Flow cytometry was applied to determine the platelets and leukocyte number. The growth factor concentration was quantified 1 and 24 h after clotting using ELISA.

Results: Reducing RCF in accordance with protocol-II (177 g) led to a significantly higher platelets and leukocytes numbers compared to protocol-I (710 g). Protocol-III (44 g) showed a highly significant increase of leukocytes and platelets number in comparison to -I and -II. The growth factors' concentration of VEGF and TGF-β1 was significantly higher in protocol-II compared to -I, whereas protocol-III exhibited significantly higher growth factor concentration compared to protocols-I and -II. These findings were observed among 1 and 24 h after clotting, as well as the accumulated growth factor concentration over 24 h.

Discussion: Based on the results, it has been demonstrated that it is possible to enrich PRF-based fluid matrices with leukocytes, platelets and growth factors by means of a single alteration of the centrifugation settings within the clinical routine.

Conclusions: We postulate that the so-called low speed centrifugation concept (LSCC) selectively enriches leukocytes, platelets and growth factors within fluid PRF-based matrices. Further studies are needed to evaluate the effect of cell and growth factor enrichment on wound healing and tissue regeneration while comparing blood concentrates gained by high and low RCF.

Keywords: A-PRF+; Centrifugation; I-PRF; Inflammation; Leukocytes; Pain; Platelet-rich fibrin; Platelets; Tissue engineering.

Conflict of interest statement

Joseph Choukroun and Shahram Ghanaati declare that they have no conflict of interest. Choukroun is the owner of PROCESS. None of the present protocols have been yet approved for clinical application.

Figures

Fig. 1
Fig. 1
a Number of leukocytes within the different experimental PRF-based matrices. b Donor-related leukocyte number within the different experimental PRF-based matrices
Fig. 2
Fig. 2
a Number of platelets within the different experimental PRF-based matrices. b Donor-related platelet number within the different experimental PRF-based matrices
Fig. 3
Fig. 3
a VEGF concentration within the different experimental PRF-based matrices 1 h after clotting. b VEGF concentration within the different experimental PRF-based matrices 24 h after clotting. c Accumulated VEGF concentration within the different experimental PRF-based matrices over 24 h
Fig. 4
Fig. 4
a TGF β-1 concentration within the different experimental PRF-based matrices 1 h after clotting. b TGF β-1 concentration within the different experimental PRF-based matrices 24 h after clotting. c Accumulated TGF β-1 concentration within the different experimental PRF-based matrices over 24 h

References

    1. Ghanaati S, Kovács A, Barbeck M, Lorenz J, Teiler A, Sadeghi N, et al. Bilayered, non-cross-linked collagen matrix for regeneration of facial defects after skin cancer removal: a new perspective for biomaterial-based tissue reconstruction. J Cell Commun Signal. 2016;10:3–15. doi: 10.1007/s12079-015-0313-7.
    1. Tsaryk R, Gloria A, Russo T, Anspach L, De Santis R, Ghanaati S, et al. Collagen-low molecular weight hyaluronic acid semi-interpenetrating network loaded with gelatin microspheres for cell and growth factor delivery for nucleus pulposus regeneration. Acta Mater Inc. 2015;20:10–21.
    1. Schlee M, Ghanaati S, Willershausen I, Stimmlmayr M, Sculean A, Sader RA. Bovine pericardium based non-cross linked collagen matrix for successful root coverage, a clinical study in human. Head Face Med BioMed Central Ltd. 2012;8:6. doi: 10.1186/1746-160X-8-6.
    1. Lorenz J, Blume M, Barbeck M, Teiler A, Kirkpatrick CJ, Sader RA, et al. Expansion of the peri-implant attached gingiva with a three-dimensional collagen matrix in head and neck cancer patients-results from a prospective clinical and histological study. Clin Oral Investig. 2016.
    1. Sauerbier S, Rickert D, Gutwald R, Nagursky H, Oshima T, Xavier SP, et al. Bone marrow concentrate and bovine bone mineral for sinus floor augmentation: a controlled, randomized, single-blinded clinical and histological trial-per-protocol analysis. Tissue Eng Part A. 2011;17:2187–2197. doi: 10.1089/ten.tea.2010.0516.
    1. Duttenhoefer F, Hieber SF, Stricker A, Schmelzeisen R, Gutwald R, Sauerbier S. Follow-up of implant survival comparing ficoll and bone marrow aspirate concentrate methods for hard tissue regeneration with mesenchymal stem cells in humans. Biores Open Access. 2014;3:75–76. doi: 10.1089/biores.2014.0003.
    1. Springer ING, Açil Y, Kuchenbecker S, Bolte H, Warnke PH, Abboud M, et al. Bone graft versus BMP-7 in a critical size defect-cranioplasty in a growing infant model. Bone. 2005;37:563–569. doi: 10.1016/j.bone.2005.05.010.
    1. Liu Y, Möller B, Wiltfang J, Warnke PH, Terheyden H. Tissue engineering of a vascularized bone graft of critical size with an osteogenic and angiogenic factor-based in vivo bioreactor. Tissue Eng Part A. 2014;20:3189–3197. doi: 10.1089/ten.tea.2013.0653.
    1. Anitua E, Andia I, Sanchez M. PRGF plasma rich growth factors. Dent Dialogue. 2004;1–9.
    1. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 1998;85:638–646. doi: 10.1016/S1079-2104(98)90029-4.
    1. Everts P a M, Knape JT a, Weibrich G, Schönberger JP a M, Hoffmann J, Overdevest EP, et al. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006;38:174–187.
    1. Anitua E, Sánchez M, Orive G, Andía I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007;28:4551–4560. doi: 10.1016/j.biomaterials.2007.06.037.
    1. Choukroun J, Adda F, Schoeffler C, Vervelle A. An opportunity in paro-implantology: PRF [in French] Implantodontie. 2001;42:55–62.
    1. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453:314–321. doi: 10.1038/nature07039.
    1. Litvinov RI, Weisel JW. What is the biological and clinical relevance of fibrin? Semin Thromb Hemost. 2016;42:333–343. doi: 10.1055/s-0036-1571342.
    1. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood. 2000;96:3772–3778.
    1. van Hinsbergh VW, a Collen, Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci. 2001;936:426–437. doi: 10.1111/j.1749-6632.2001.tb03526.x.
    1. Soloviev DA, Hazen SL, Szpak D, Bledzka KM, Ballantyne CM, Plow EF, et al. Dual role of the leukocyte integrin M 2 in angiogenesis. J Immunol. 2014;193:4712–4721. doi: 10.4049/jimmunol.1400202.
    1. Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, et al. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implantol. 2014;40:679–689. doi: 10.1563/aaid-joi-D-14-00138.
    1. Quirke P, Dyson JED. J Pathol. 1986;149:79–87. doi: 10.1002/path.1711490202.
    1. Keith Wilson JW. Principles and techniques of biochemistry and molecular biology. Cambridge: Cambridge University Press;2010.
    1. Kawazoe T, Kim HH. Tissue augmentation by white blood cell-containing platelet-rich plasma. Cell Transplant. 2012;21:601–607. doi: 10.3727/096368911X605538.
    1. Omar OM, Granéli C, Ekström K, Karlsson C, Johansson A, Lausmaa J, et al. The stimulation of an osteogenic response by classical monocyte activation. Biomaterials. 2011;32:8190–8204. doi: 10.1016/j.biomaterials.2011.07.055.
    1. Pirraco RP, Reis RL, Marques AP. Effect of monocytes/macrophages on the early osteogenic differentiation of hBMSCs. J Tissue Eng Regen Med. 2013;7:392–400. doi: 10.1002/term.535.
    1. Ekström K, Omar O, Granéli C, Wang X, Vazirisani F, Thomsen P. Monocyte exosomes stimulate the osteogenic gene expression of mesenchymal stem cells. PLoS One. 2013;8:e75227. doi: 10.1371/journal.pone.0075227.
    1. Perut F, Filardo G, Mariani E, Cenacchi A, Pratelli L, Devescovi V, et al. Preparation method and growth factor content of platelet concentrate influence the osteogenic differentiation of bone marrow stromal cells. Cytotherapy. 2013;15:830–839. doi: 10.1016/j.jcyt.2013.01.220.
    1. Tan KW, Chong SZ, Wong FHS, Evrard M, Tan SM-L, Keeble J, et al. Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D. Blood. 2013;122:3666–3677. doi: 10.1182/blood-2012-11-466532.
    1. Schär MO, Diaz-Romero J, Kohl S, Zumstein MA, Nesic D. Platelet-rich concentrates differentially release growth factors and induce cell migration in vitro. Clin Orthop Relat Res. 2015;473:1635–1643. doi: 10.1007/s11999-015-4192-2.
    1. Nami N, Feci L, Napoliello L, Giordano A, Lorenzini S, Galeazzi M, et al. Crosstalk between platelets and PBMC: new evidence in wound healing. Platelets. 2016;27:143–148.
    1. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005;31:381–92.
    1. Walsh TG, Metharom P, Berndt MC. The functional role of platelets in the regulation of angiogenesis. Platelets. 2015;26:199–211. doi: 10.3109/09537104.2014.909022.
    1. Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol. 2013;35:254–261. doi: 10.1111/ijlh.12084.
    1. Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nat Rev Microbiol. 2014;12:426–437. doi: 10.1038/nrmicro3269.
    1. Schmidt-Bleek K, Kwee BJ, Mooney DJ, Duda GN. Boon and bane of inflammation in bone tissue regeneration and its link with angiogenesis. Tissue Eng Part B Rev. 2015;21:354–364. doi: 10.1089/ten.teb.2014.0677.
    1. Moens S, Goveia J, Stapor PC, Cantelmo AR, Carmeliet P. The multifaceted activity of VEGF in angiogenesis—implications for therapy responses. Cytokine Growth Factor Rev. 2014;25:473–482. doi: 10.1016/j.cytogfr.2014.07.009.
    1. Lichtman MK, Otero-Vinas M, Falanga V. Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis. Wound Repair Regen. 2016;215–22.
    1. Kim B-C, Kim HT, Park SH, Cha J-S, Yufit T, Kim S-J, et al. Fibroblasts from chronic wounds show altered TGF-β-signaling and decreased TGF-? Type II receptor expression. J Cell Physiol. 2003;195:331–336. doi: 10.1002/jcp.10301.
    1. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 1986;83:4167–71.
    1. Barbeck M, Unger RE, Booms P, Dohle E, Sader RA, Kirkpatrick CJ, et al. Monocyte preseeding leads to an increased implant bed vascularization of biphasic calcium phosphate bone substitutes via vessel maturation. J Biomed Mater Res Part A. 2016;1–8.
    1. Davis VL, Abukabda AB, Radio NM, Witt-Enderby PA, Clafshenkel WP, Cairone JV, et al. Platelet-rich preparations to improve healing. Part II: platelet activation and enrichment, leukocyte inclusion, and other selection criteria. J Oral Implantol. 2014;40:511–521. doi: 10.1563/AAID-JOI-D-12-00106.
    1. Ghasemzadeh M, Hosseini E. Intravascular leukocyte migration through platelet thrombi: directing leukocytes to sites of vascular injury. Thromb Haemost. 2015;113:1224–1235. doi: 10.1160/TH14-08-0662.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera